Advertisement
Table 3 Adverse events that occurred during the study
| Pelubiprofen (n =77) | Celecoxib (n =68) | ||||
|---|---|---|---|---|---|
| Patients, n (%) | Events, n | Patients, n (%) | Events, n | p-value* | |
| Total adverse events | 39 (50.6) | 62 | 25 (36.8) | 33 | 0.09 |
| Gastrointestinal | 21 (27.3) | 29 | 7 (10.3) | 8 | 0.01 |
| Anorexia | 2 (2.6) | 2 | 1 (1.47) | 1 | |
| Nausea | 2 (2.6) | 3 | 3 (4.41) | 3 | |
| Vomiting | 1 (1.3) | 1 | 1 (1.47) | 1 | |
| Indigestion | 3 (3.9) | 2 | 1 (1.47) | 1 | |
| Epigastric discomfort | 4 (5.2) | 4 | 0 (0.0) | 0 | |
| Abdominal pain | 10 (13.0) | 10 | 2 (2.94) | 2 | |
| Diarrhea | 4 (5.19) | 5 | 0 (0.0) | 0 | |
| Constipation | 2 (2.6) | 2 | 0 (0.0) | 0 | |
| Systemic | 11 (14.3) | 13 | 4 (5.9) | 4 | 0.10 |
| Facial edema | 5 (6.49) | 5 | 1 (1.5) | 1 | |
| Edema | 4 (5.19) | 5 | 1 (1.5) | 1 | |
| Chest discomfort | 1 (1.3) | 1 | 0 (0.0) | 0 | |
| Nipple pain | 0 (0.0) | 0 | 1 (1.5) | 1 | |
| Weight gain | 0 (0.0) | 0 | 1 (1.5) | 1 | |
| Pain | 1 (1.3) | 1 | 0 (0.0) | 0 | |
| Fatigue | 1 (1.3) | 1 | 0 (0.0) | 0 | |
| Anemia | 0 (0.0) | 0 | 1 (1.5) | 1 | 0.29 |
| Respiratory | 6 (7.8) | 6 | 4 (5.9) | 4 | 0.65 |
| Nervous system | 2 (2.6) | 2 | 4 (5.9) | 6 | 0.32 |
| Skin and appendage | 3 (3.9) | 4 | 1 (1.5) | 1 | 0.37 |
| Musculoskeletal | 1 (1.3) | 1 | 2 (2.9) | 2 | 0.49 |
| Hepatobiliary | 1 (1.3) | 1 | 1 (1.5) | 2 | 0.92 |
| Reproductive system | 1 (1.3) | 1 | 1 (1.5) | 2 | 0.92 |
| Cardiovascular | 1 (1.3) | 1 | 1 (1.5) | 1 | 0.92 |
| Infection | 0 (0.0) | 0 | 1 (1.5) | 1 | 0.29 |
| Eye | 1 (1.3) | 1 | 0 (0.0) | 0 | 0.35 |
| Urinary | 1 (1.3) | 1 | 0 (0.0) | 0 | 0.35 |
| Psychiatric | 1 (1.3) | 2 | 0 (0.0) | 0 | 0.35 |
| Peripheral vascular | 0 (0.0) | 0 | 1 (1.5) | 1 | 0.29 |
